The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, The University of Manchester , Salford, UK.
Expert Opin Biol Ther. 2020 Nov;20(11):1245-1251. doi: 10.1080/14712598.2020.1822813. Epub 2020 Sep 25.
The therapeutic landscape for psoriasis is ever-changing. Risankizumab is the newest approved biologic and one of three currently licensed that targets the p19 subunit of interleukin-23 (IL-23). It is increasingly clear that different biologics vary in their efficacy, effectiveness, and safety profiles, highlighting that there is a need to understand for which patients and in which circumstances to use each drug.
This article summarizes original clinical trial data, and reviews in more detail recent post-marketing studies and meta-analyses that differentiate risankizumab from other biologics. It also briefly explores the evidence for risankizumab in the treatment of other immune-mediated inflammatory diseases.
Risankizumab is a highly effective biologic for the treatment of moderate-to-severe plaque psoriasis. Recent open-label extension data for risankizumab shows sustained treatment responses to week 136. Indirect comparisons suggest IL-17 inhibitors have a faster onset, though head-to-head comparison with secukinumab shows non-inferiority at week 16 and superiority of risankizumab at week 52. Risankizumab is very well tolerated and data from the IMMhance trial suggests that risankizumab can be used in patients with latent tuberculosis without risk of reactivation.
银屑病的治疗领域在不断变化。里萨鲁单抗是最新获批的生物制剂，也是目前三种靶向白细胞介素-23（IL-23）p19 亚单位的生物制剂之一。越来越明显的是，不同的生物制剂在疗效、有效性和安全性方面存在差异，这突出表明需要了解每种药物适用于哪些患者和在哪些情况下使用。
本文总结了原始临床试验数据，并更详细地回顾了最近的上市后研究和荟萃分析，这些研究将里萨鲁单抗与其他生物制剂区分开来。它还简要探讨了里萨鲁单抗在治疗其他免疫介导的炎症性疾病中的证据。
里萨鲁单抗是一种治疗中重度斑块状银屑病的高效生物制剂。最近的里萨鲁单抗开放性扩展数据显示，治疗反应可持续至第 136 周。间接比较表明，IL-17 抑制剂起效更快，尽管与司库奇尤单抗的头对头比较显示第 16 周非劣效性，第 52 周里萨鲁单抗更优。里萨鲁单抗具有良好的耐受性，来自 IMMhance 试验的数据表明，里萨鲁单抗可用于潜伏性结核患者，不会有再激活的风险。
